Search Results

Classes will be live from Zoom on Thursdays from 10 am to 11:30 am EST. Sessions will include a 1-hour live lecture plus 30 minutes of Q&A.

- Appreciating the practical realities, limitations, and tradeoffs of GPCR data analysis. analysis Module 4 - New dimensions of activity: Allosteric modulators and kinetics Classes will be live Sessions will include a one-hour live lecture plus one hour of Q&A and discussion.

October 2022 Structural perspectives on the mechanism of signal activation, ligand selectivity and allosteric tissue response to a given dose of the hormone or its antagonist depends on receptors that engage the ligand Thus, we need to know much more about the structures of receptor-ligand complexes at high resolution. , X-ray structures of both AngII receptors (AT1 and AT2 receptors) bound to peptide and non-peptide ligands Constituent structural motifs cooperatively transform ligand selectivity into specific functions, thus

Intriguingly, the two ligands have distinct signaling and physiological properties: PTH evokes prolonged The distinct molecular actions are ascribed to the differences in ligand recognition and dissociation A comparison of the PTH-bound and PTHrP-bound structures reveals distinct ligand-receptor interactions underlying the ligand affinity and selectivity. dissociation from the receptor and shed light on the distinct durations of signaling induced by PTH

October 2022 Mechanism of enhanced sensitivity of mutated β-adrenergic-like octopamine receptor to amitraz Previous assays verified that a typical G protein-coupled receptor, β-adrenergic-like octopamine receptor

In an in vivo study, the effects of RGS6 knockout were studied in a mouse model of ALI induced by lipopolysaccharide Authors Juan Song , Miao Li , Cuicui Chen , Jian Zhou , Linlin Wang , Yu Yan , Jun She , Lin Tong , Yuanlin

To investigate potential mechanisms underlying this synergistic pharmacodynamic interaction, liquid chromatography-mass Authors Xin Miao , Gilbert Koch , Shichen Shen , Xue Wang , Jun Li , Xiaomeng Shen , Jun Qu , Robert

The lung cancer cell line H1299-BRS3 was treated with MK-5046, an agonist of BRS3, for different durations Authors Miao Guo , Yan Zhang , Lehao Wu , Ye Sheng , Jiaqi Zhao , Zeyuan Wang , Huiyu Wang , Lu Zhang , Hua Xiao Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News